Zacks Investment Research
17 Jun 2026, 11:51 UTC · 14w ago
Verdict
Headline takes no side. We score MIRM +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
The FDA has accepted the New Drug Application (NDA) for zilurgisertib for the treatment of fibrodysplasia ossificans progressiva (FOP) and granted it Priority Review status.
More positive than 99% of claims this week
Zilurgisertib demonstrated positive pivotal phase II results in the PROGRESS study, reducing the proportion of patients with new heterotopic ossification lesions.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 93% of claims this week
The FDA is expected to deliver its decision regarding the NDA for zilurgisertib by September 26, 2026.
More positive than 66% of claims this week
Mirum Pharmaceuticals (MIRM) holds the worldwide development and commercialization rights for zilurgisertib, which was licensed from Incyte Corporation (INCY).
More positive than 54% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Reported positive pivotal phase II results and received FDA Priority Review status for zilurgisertib.
More positive than 88% of ticker scores this week
Reported positive pivotal phase II results and is the licensor of the drug receiving FDA Priority Review.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
1h ago
−13.3%
Price is moving against the score
$88.03 vs $101.55 close before publication (Jun 16) · not market-adjusted
MIRM chart →
